Streetbeat News

Revenues

EYPT

EyePoint Pharmaceuticals (NASDAQ:EYPT) has been evaluated by 4 analysts over the past three months, with ratings ranging from bullish to bearish. The average 12-month price target has decreased by 25.81% to $23.0. Analysts have maintained or adjusted their ratings and price targets, reflecting their views on the company's market position. EyePoint Pharmaceuticals is focused on developing ophthalmic products and has shown revenue growth, though it lags behind industry peers. The company faces challenges in profitability but maintains a prudent debt management strategy.

Portfolio Pulse from Benzinga Insights

October 25, 2024 | 2:01 pm

LH

Over the past three months, 12 analysts have shared their insights on Labcorp Holdings (NYSE:LH), with ratings ranging from bullish to bearish. The average 12-month price target has increased by 3.42% to $258.83. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance. Labcorp Holdings has shown strong financial performance with a 6.17% revenue growth rate, a 6.37% net margin, and a balanced debt-to-equity ratio of 0.75.

Portfolio Pulse from Benzinga Insights

October 25, 2024 | 2:00 pm

ALLE

Analysts have varied ratings for Allegion (NYSE:ALLE) over the last quarter, with most being indifferent. Recent evaluations show a positive shift in price targets, with an average target of $147.25, up 10.3% from the previous $133.50. Allegion has shown strong financial performance with a 5.82% revenue growth rate and a net margin of 16.09%, but faces challenges with a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

October 25, 2024 | 2:00 pm

SPY

The University of Michigan's Consumer Sentiment Index for October rose to 70.5, surpassing the estimated 68.9 and the previous month's 68.9. This indicates improved consumer confidence.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 2:00 pm

NTLA

Intellia Therapeutics (NASDAQ:NTLA) has received mixed analyst ratings over the past three months, with a decrease in the average 12-month price target from $62.17 to $53.43. Analysts have adjusted their ratings and price targets in response to market conditions and company performance. Intellia is a gene editing company focused on Crispr/Cas9-based therapeutics, facing challenges with a -48.82% revenue growth decline and a high net margin of -2112.62%.

Portfolio Pulse from Benzinga Insights

October 25, 2024 | 2:00 pm

GPK

Graphic Packaging Holding (NYSE:GPK) has outperformed the market over the past 15 years with an average annual return of 18.83%, significantly boosting investor returns through compounded growth.

Portfolio Pulse from Benzinga Insights

October 25, 2024 | 2:00 pm

SPY

The Michigan Consumer Expectations index for October rose to 74.1, surpassing the estimated 72.9 and the previous month's figure of 72.9. This indicates improved consumer sentiment.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 2:00 pm

AIT

Applied Industrial Techs (NYSE:AIT) has significantly outperformed the market over the past 5 years, with an annualized return of 32.39%. A $1000 investment in AIT 5 years ago would now be worth $4,098.02, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

October 25, 2024 | 2:00 pm

DOW

In the past three months, analysts have shown mixed sentiments towards Dow (NYSE:DOW), with most ratings being indifferent. The average 12-month price target has decreased by 5.59% to $55.43. Analysts have lowered their price targets, reflecting a cautious outlook. Despite a decline in revenue growth, Dow maintains strong financial metrics such as net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

October 25, 2024 | 2:00 pm

COF

GLD

SPY

The S&P 500 index saw an increase, with Capital One's stock rising due to an earnings beat. Meanwhile, gold prices and Treasury yields experienced a pullback.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 1:44 pm